These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1208 related articles for article (PubMed ID: 33010357)

  • 21. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
    Chen RJ; Chu H; Tsai LW
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28073770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality.
    Abbott KC; Trespalacios FC; Agodoa LY; Taylor AJ; Bakris GL
    Arch Intern Med; 2004 Dec 13-27; 164(22):2465-71. PubMed ID: 15596637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
    Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
    Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis.
    Wu PH; Lin YT; Kuo MC; Liu JS; Tsai YC; Chiu YW; Carrero JJ
    Nephrol Dial Transplant; 2020 Nov; 35(11):1959-1965. PubMed ID: 32719861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based analysis of class effect of β blockers in heart failure.
    Lazarus DL; Jackevicius CA; Behlouli H; Johansen H; Pilote L
    Am J Cardiol; 2011 Apr; 107(8):1196-202. PubMed ID: 21349489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
    Shore S; Aggarwal V; Zolty R
    J Card Fail; 2012 Dec; 18(12):919-24. PubMed ID: 23207080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
    BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
    Sessa M; Rasmussen DB; Jensen MT; Kragholm K; Torp-Pedersen C; Andersen M
    Am J Cardiol; 2020 Apr; 125(7):1069-1076. PubMed ID: 32000982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
    Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.
    Gurwitz JH; Magid DJ; Smith DH; Tabada GH; Sung SH; Allen LA; McManus DD; Goldberg RJ; Tisminetzky M; Go AS
    J Am Geriatr Soc; 2017 Dec; 65(12):2610-2618. PubMed ID: 28873219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate.
    Lam PH; Gupta N; Dooley DJ; Singh S; Deedwania P; Zile MR; Bhatt DL; Morgan CJ; Pitt B; Fonarow GC; Ahmed A
    Am J Med; 2018 Dec; 131(12):1473-1481. PubMed ID: 30076815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blocker benefit according to severity of heart failure.
    Bouzamondo A; Hulot JS; Sanchez P; Lechat P
    Eur J Heart Fail; 2003 Jun; 5(3):281-9. PubMed ID: 12798825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of different beta-blockers in the treatment of long QT syndrome.
    Abu-Zeitone A; Peterson DR; Polonsky B; McNitt S; Moss AJ
    J Am Coll Cardiol; 2014 Sep; 64(13):1352-8. PubMed ID: 25257637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.